OpenAlex
PricingAboutJobs
Log inGet started
Work

Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy

HTML

Year: 2006
Type: article
Study design: Clinical Trial
Source: Cancer
DOI: 10.1002/cncr.21834
Authors: Ken Wyman, Michael B. Atkins, Victor Prieto, Omar Eton, David F. McDermott, Francie Hubbard, Christine Byrnes, Kathleen Sanders, Jeffrey A. Sosman
Institutions: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Harvard University, The University of Texas MD Anderson Cancer Center
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: imatinib mesylate, metastatic melanoma, tyrosine kinase inhibitors, CD117, PDGFRA, PDGFRβ, BCR-ABL, kinase expression, treatment response, progression-free survival
SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute
Awards: Clinical Investigation in Tumor Immunotherapy, G3479953482
OpenAlex ID: W2015682571
FWCI: 8.181
Cites: 28
Cited by: 288
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms